Cullinan Therapeutics Valuation Multiples

Cullinan Therapeutics Overview

About Cullinan Therapeutics

Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.

Founded

2016

HQ

Employees

111

Website

cullinantherapeutics.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $6M

EBITDA: ($227M)

EV

$632M

Valuation Multiples

Multiples.vc

Start free trial

Cullinan Therapeutics Financials

Cullinan Therapeutics reported last 12-month revenue of $6M and negative EBITDA of ($227M).

In the same LTM period, Cullinan Therapeutics generated $6M in gross profit, ($227M) in EBITDA losses, and had net loss of ($215M).

Cullinan Therapeutics P&L

In the most recent fiscal year, Cullinan Therapeutics reported revenue of — and EBITDA of ($241M).

Cullinan Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX

Cullinan Therapeutics Stock Performance

Cullinan Therapeutics has current market cap of $963M, and enterprise value of $632M.

Cullinan Therapeutics' stock price is $16.30.

Cullinan Therapeutics Valuation Multiples

Cullinan Therapeutics trades at 109.4x EV/Revenue multiple, and (2.8x) EV/EBITDA.

Cullinan Therapeutics Financial Valuation Multiples

As of March 21, 2026, Cullinan Therapeutics has market cap of $963M and EV of $632M.

Equity research analysts estimate Cullinan Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Cullinan Therapeutics has a P/E ratio of (4.5x).

Cullinan Therapeutics Margins & Growth Rates

Cullinan Therapeutics' revenue in the last 12 month grew by 392%.

Cullinan Therapeutics' revenue per employee in the last FY averaged $0.1M.

Cullinan Therapeutics' rule of 40 is (3533%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Cullinan Therapeutics' rule of X is (2945%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Cullinan Therapeutics Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Cullinan Therapeutics M&A Activity

Cullinan Therapeutics acquired XXX companies to date.

Last acquisition by Cullinan Therapeutics was on XXXXXXXX, XXXXX. Cullinan Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Cullinan Therapeutics Investment Activity

Cullinan Therapeutics invested in XXX companies to date.

Cullinan Therapeutics made its latest investment on XXXXXXXX, XXXXX. Cullinan Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).